A839977 (A-839977) is a novel and potent P2X7R antagonist with antihyperalgesic and anti-inflammatory activity.

A-740003 is a potent and selective P2X7 receptor antagonist.

Clopidogrel sulfate (Plavix; Zyllt; Osvix; Plavitor, SR-25990C), the sulfate salt of Clopidogrel, is an orally bioavailable, thienopyridine class of antiplatelet agent acting as an irreversible inhibitor of ADP receptor (P2Y12).

A-438079 HCl (A438079; A 438079), the hydrochloride salt of -438079, is a novel, potent, and selective P2X7 receptor antagonist with anti-Parkinson’s disease effects.

AF-353 (Ro-4; AF353) is a novel, highly potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3.

Ticlopidine HCl (Ticlodix; Ticlodone; 53-32C; 5332C; trade name Ticlid), the hydrochloride salt of ticlopidine, is a potent P2 receptor inhibitor against used as antiplatelet and anticoagulant.

A-804598 (A 804598) is a structurally novel, CNS penetrant, potent, competitive, and selective antagonist of the purinergic P2X7 receptors (IC50 = 10 nM, 9 nM and 11 nM for rat, mouse and human P2X7 receptors respectively) with potential anti-inflammatory activity.

MRS2578 (MRS-2578; MRS 2578) is a potent and selective P2Y6 receptor antagonist with potentially usefulness in controlling persistent storage symptoms in obstructed patients.

Prasugrel (formerly CS-747, PCR-4099; LY-640315; trade name Effient; Prasita), a piperazine derivative, is an irreversible and thienopyridine-based ADP receptor (P2Y12) antagonist approved as an antiplatelet and anticoagulant drug used for the reduction of thrombotic cardiovascular events.

BX430 is a novel, potent, selective allosteric/con-competitive antagonist of human P2X4 receptor channels with an IC50 of 0.54 μM.